P53

Calluna Pharma is a clinical-stage company focused on developing innovative therapies that leverage the body's immune system to treat various immunological diseases. The company has established a strong pipeline of selective antibodies aimed at addressing unmet clinical needs across a range of conditions. Its approach includes precision targeting of upstream innate immune amplifiers and the disruption of disease-associated downstream signaling pathways, all while ensuring a favorable safety profile for its therapeutic candidates. Through its research and development efforts, Calluna Pharma aims to transform treatment options for patients suffering from immunological disorders.

Teitur Trophics is a biotech company based in Aarhus, Denmark, established in 2020. The company focuses on developing circular peptides aimed at addressing neurodegenerative diseases. By studying small peptides that interact with receptors crucial for neural function, Teitur Trophics aims to understand the underlying biology and modulate key mechanisms involved in neural activity. This research is intended to support healthcare professionals in creating treatments that can prevent the onset of neurodegenerative conditions through daily injections.